A New Frontier in the Fight Against Cancer

| March 7, 2019

article image
Pathology studies the causes and effects of cancer and other diseases.  Pathologists work by examining tissue samples in a laboratory.  But with the advent of personalized medicine, the pathologist’s role is profoundly changing. Traditionally, pathologists were viewed as “diagnosticians working behind closed doors,” says Dr. Carol Cheung with the University of Toronto.  But increasingly, pathologists are moving out of the laboratory and into the clinic to work directly with their patients.

Spotlight

iMEDGlobal Corporation

iMEDGlobal, an FMD K&L company, is an innovation-driven company providing platforms, services, and solutions to global life sciences clients to address critical business and scientific needs. Our platforms, services, and solutions include Pharmacovigilance, Regulatory Affairs, and Clinical Research. Led by a strong management team with decades of experience and thought leadership with leading pharmaceutical, biotech, medical devices, cosmetic and technology enterprises, iMEDGlobal is designed to deliver high-quality cost-effective solutions and services for our clients in the Americas, Europe, Asia and Australia. iMEDGlobal is a preferred partner to many top global life sciences companies who have placed their trust in our management team, infrastructure and capabilities.

OTHER ARTICLES

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 1, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 1, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | March 1, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

Spotlight

iMEDGlobal Corporation

iMEDGlobal, an FMD K&L company, is an innovation-driven company providing platforms, services, and solutions to global life sciences clients to address critical business and scientific needs. Our platforms, services, and solutions include Pharmacovigilance, Regulatory Affairs, and Clinical Research. Led by a strong management team with decades of experience and thought leadership with leading pharmaceutical, biotech, medical devices, cosmetic and technology enterprises, iMEDGlobal is designed to deliver high-quality cost-effective solutions and services for our clients in the Americas, Europe, Asia and Australia. iMEDGlobal is a preferred partner to many top global life sciences companies who have placed their trust in our management team, infrastructure and capabilities.

Events